Bifogade filer
Lipidor adds 1.1 MSEK through sale of shares in associated company and agreement of loan
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
STOCKHOLM, Sweden, 21st December 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that 63 shares, corresponding to approximately 0.5 MSEK, have been sold in the associated company Emollivet, and that a loan of approximately 0.6 MSEK has been taken up from the company's largest owner, Cerbios-Pharma SA.
In 2023, Lipidor has made a phased divestment of its holding in the associated company Emollivet and today another transaction is announced. A total of 63 shares in Emollivet have been sold to Cerbios-Pharma SA at a price per share of SEK 7,290. The price has been determined through an external valuation of Emollivet carried out by independent advisors. Through the transaction, Lipidor will receive approximately 0.5 MSEK and after the transaction, Lipidor will continue to own 253 shares in Emollivet.
An interest-free loan of approximately 0.6 MSEK has also been raised from the company's largest shareholder Cerbios-Pharma SA and repayment is made with Emollivet shares. The loan matures on 1 March 2024. The size of the loan corresponds to 89 shares at a price of SEK 7,290 per share.
The plan is also to find a taker for the remaining ownership in Emollivet and to work towards the possibility of using IP linked to the animal segment for additional bridge financing.